Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb;82(4):772–776. doi: 10.1054/bjoc.1999.0997

Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study

C M L van Herpen 1, R L H Jansen 2, W H J Kruit 3, K Hoekman 4, G Groenewegen 5, S Osanto 6, P H M De Mulder 1
PMCID: PMC2374413  PMID: 10732744

Abstract

In patients with metastatic renal cell carcinoma response rates of 7–26% have been achieved with immunotherapy. A high response rate of 48% in 35 patients has been reported for treatment with the combination of interferon-α (IFN-α), interleukin-2 (IL-2) and 5-fluorouracil (5-FU) (Atzpodien et al (1993 a) Eur J Cancer29A: S6–8). We conducted a multicentre phase II study to confirm these results. Metastatic renal cell carcinoma patients were treated as outpatients with an 8-week treatment cycle. Recombinant human IL-2 20 MU m−2was administered subcutaneously (s.c.) three times a week (t.i.w) in weeks 1 and 4 and 5 MU m−2t.i.w. in weeks 2 and 3. Recombinant human IFN-α 2a 6 MU m−2was administered s.c. once in weeks 1 and 4 and t.i.w. in weeks 2 and 3, and 9 MU m−2t.i.w. in weeks 5–8. 5-FU (750 mg m−2) was given as a bolus injection intravenous once a week in weeks 5–8. The treatment cycle was repeated once in case of response or minor response. Fifty-two patients entered the study. All had undergone a nephrectomy and had progressive metastatic disease. The median WHO-performance status was 1, the median number of metastatic sites was 2 (range 1–5) and the median time between the diagnosis of the primary tumour and the start of treatment was 12.9 months (range 1–153). Among the 51 patients, including four patients with early progressive disease, who were evaluable for response, the response rate was 11.8% (95% confidence interval (CI) 2.9–20.7%), with no complete responses. Median duration of response was 8.3 (range 3.8–22.4+) months. Median survival was 16.5 (range 1.8–30.5+) months. Grade 3/4 toxicity (WHO) occurred in 29/52 (55.8%) of the patients in cycle 1 and in 6/16 (37.5%) of the patients in cycle 2. It consisted mainly of anorexia, fatigue, nausea, fever and leucocytopenia. We cannot confirm the high response rate in patients with metastatic renal cell carcinoma treated with the combination of IFN-α, IL-2 and 5-FU, as described by Atzpodien et al. © 2000 Cancer Research Campaign

Keywords: immunochemotherapy, renal cell carcinoma, phase II, interleukin-2, interferon-α, 5-FU

Full Text

The Full Text of this article is available as a PDF (69.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Kirchner H., Hänninen E. L., Deckert M., Fenner M., Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer. 1993;29A Suppl 5:S6–S8. doi: 10.1016/0959-8049(93)90617-o. [DOI] [PubMed] [Google Scholar]
  2. Atzpodien J., Kirchner H., Hänninen E. L., Körfer A., Fenner M., Menzel T., Deckert M., Franzke A., Jonas U., Poliwoda H. European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol. 1993 Dec;20(6 Suppl 9):22–26. [PubMed] [Google Scholar]
  3. Atzpodien J., Lopez Hänninen E., Kirchner H., Bodenstein H., Pfreundschuh M., Rebmann U., Metzner B., Illiger H. J., Jakse G., Niesel T. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995 Feb;13(2):497–501. doi: 10.1200/JCO.1995.13.2.497. [DOI] [PubMed] [Google Scholar]
  4. Creagan E. T., Twito D. I., Johansson S. L., Schaid D. J., Johnson P. S., Flaum M. A., Buroker T. R., Geeraerts L. H., Veeder M. H., Gesme D. H., Jr A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol. 1991 Dec;9(12):2104–2109. doi: 10.1200/JCO.1991.9.12.2104. [DOI] [PubMed] [Google Scholar]
  5. Ellerhorst J. A., Sella A., Amato R. J., Tu S. M., Millikan R. E., Finn L. D., Banks M., Logothetis C. J. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer. 1997 Dec 1;80(11):2128–2132. [PubMed] [Google Scholar]
  6. Facendola G., Locatelli M. C., Pizzocaro G., Piva L., Pegoraro C., Pallavicini E. B., Signaroldi A., Meregalli M., Lombardi F., Beretta G. D. Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer. 1995 Dec;72(6):1531–1535. doi: 10.1038/bjc.1995.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fosså S. D., Kramar A., Droz J. P. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer. 1994;30A(9):1310–1314. doi: 10.1016/0959-8049(94)90179-1. [DOI] [PubMed] [Google Scholar]
  8. Fyfe G. A., Fisher R. I., Rosenberg S. A., Sznol M., Parkinson D. R., Louie A. C. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996 Aug;14(8):2410–2411. doi: 10.1200/JCO.1996.14.8.2410. [DOI] [PubMed] [Google Scholar]
  9. Gleave M. E., Elhilali M., Fradet Y., Davis I., Venner P., Saad F., Klotz L. H., Moore M. J., Paton V., Bajamonde A. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998 Apr 30;338(18):1265–1271. doi: 10.1056/NEJM199804303381804. [DOI] [PubMed] [Google Scholar]
  10. Gore M. E., Galligioni E., Keen C. W., Sorio R., Loriaux E. M., Grobben H. C., Franks C. R. The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. Eur J Cancer. 1994;30A(3):329–333. doi: 10.1016/0959-8049(94)90251-8. [DOI] [PubMed] [Google Scholar]
  11. Guadagni F., Schlom J., Johnston W. W., Szpak C. A., Goldstein D., Smalley R., Simpson J. F., Borden E. C., Pestka S., Greiner J. W. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst. 1989 Apr 5;81(7):502–512. doi: 10.1093/jnci/81.7.502. [DOI] [PubMed] [Google Scholar]
  12. Hofmockel G., Langer W., Theiss M., Gruss A., Frohmüller H. G. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol. 1996 Jul;156(1):18–21. [PubMed] [Google Scholar]
  13. Jayson G. C., Middleton M., Lee S. M., Ashcroft L., Thatcher N. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer. 1998 Aug;78(3):366–369. doi: 10.1038/bjc.1998.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Joffe J. K., Banks R. E., Forbes M. A., Hallam S., Jenkins A., Patel P. M., Hall G. D., Velikova G., Adams J., Crossley A. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol. 1996 May;77(5):638–649. doi: 10.1046/j.1464-410x.1996.09573.x. [DOI] [PubMed] [Google Scholar]
  15. Jones M., Philip T., Palmer P., von der Maase H., Vinke J., Elson P., Franks C. R., Selby P. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother. 1993 Winter;8(4):275–288. doi: 10.1089/cbr.1993.8.275. [DOI] [PubMed] [Google Scholar]
  16. Kish J. A., Wolf M., Crawford E. D., Leimert J. T., Bueschen A., Neefe J. R., Flanigan R. C. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer. 1994 Aug 1;74(3):916–919. doi: 10.1002/1097-0142(19940801)74:3<916::aid-cncr2820740319>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  17. Kjaer M. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat Rev. 1988 Sep;15(3):195–209. doi: 10.1016/0305-7372(88)90003-5. [DOI] [PubMed] [Google Scholar]
  18. Lopez Hänninen E., Kirchner H., Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol. 1996 Jan;155(1):19–25. [PubMed] [Google Scholar]
  19. Negrier S., Escudier B., Lasset C., Douillard J. Y., Savary J., Chevreau C., Ravaud A., Mercatello A., Peny J., Mousseau M. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med. 1998 Apr 30;338(18):1272–1278. doi: 10.1056/NEJM199804303381805. [DOI] [PubMed] [Google Scholar]
  20. Palmer P. A., Atzpodien J., Philip T., Negrier S., Kirchner H., Von der Maase H., Geertsen P., Evers P., Loriaux E., Oskam R. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother. 1993 Summer;8(2):123–136. doi: 10.1089/cbr.1993.8.123. [DOI] [PubMed] [Google Scholar]
  21. Pfeffer L. M., Tamm I. Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake. J Cell Physiol. 1984 Nov;121(2):431–436. doi: 10.1002/jcp.1041210223. [DOI] [PubMed] [Google Scholar]
  22. Ravaud A., Audhuy B., Gomez F., Escudier B., Lesimple T., Chevreau C., Douillard J. Y., Caty A., Geoffrois L., Ferrero J. M. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie. J Clin Oncol. 1998 Aug;16(8):2728–2732. doi: 10.1200/JCO.1998.16.8.2728. [DOI] [PubMed] [Google Scholar]
  23. Reiter Z., Ozes O. N., Blatt L. M., Taylor M. W. A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity. Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 1):103–111. doi: 10.1016/0090-1229(92)90029-n. [DOI] [PubMed] [Google Scholar]
  24. Seymour M. T., Patel N., Johnston A., Joel S. P., Slevin M. L. Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. Br J Cancer. 1994 Oct;70(4):724–728. doi: 10.1038/bjc.1994.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tomita Y., Imai T., Katagiri A., Kimura M., Saitoh K., Sato S. 5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle. Cancer Lett. 1993 Nov 30;75(1):27–34. doi: 10.1016/0304-3835(93)90203-l. [DOI] [PubMed] [Google Scholar]
  26. Tourani J. M., Pfister C., Berdah J. F., Benhammouda A., Salze P., Monnier A., Paule B., Guillet P., Chretien Y., Brewer Y. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol. 1998 Jul;16(7):2505–2513. doi: 10.1200/JCO.1998.16.7.2505. [DOI] [PubMed] [Google Scholar]
  27. Umeda T., Niijima T. Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer. 1986 Sep 15;58(6):1231–1235. doi: 10.1002/1097-0142(19860915)58:6<1231::aid-cncr2820580610>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES